Qualigen Therapeutics Inc
NASDAQ:QLGN
Qualigen Therapeutics Inc
NASDAQ:QLGN
Price:
0.1957 USD
-2.15%
Market Closed
Updated:
Jun 11, 2024
Qualigen Therapeutics Inc
Additional Paid In Capital
|
Qualigen Therapeutics Inc
Additional Paid In Capital Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Additional Paid In Capital Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Additional Paid In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Qualigen Therapeutics Inc
NASDAQ:QLGN
|
Additional Paid In Capital
$114.7m
|
CAGR 3-Years
10%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Additional Paid In Capital
$20.7B
|
CAGR 3-Years
5%
|
CAGR 5-Years
7%
|
CAGR 10-Years
18%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Additional Paid In Capital
$6.8B
|
CAGR 3-Years
19%
|
CAGR 5-Years
22%
|
CAGR 10-Years
2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Additional Paid In Capital
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Additional Paid In Capital
$7.3B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
3%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Additional Paid In Capital
$11.9B
|
CAGR 3-Years
20%
|
CAGR 5-Years
23%
|
CAGR 10-Years
18%
|
See Also
What is Qualigen Therapeutics Inc's Additional Paid In Capital?
Additional Paid In Capital
114.7m
USD
114.7m
USD
Based on the financial report for Dec 31, 2023, Qualigen Therapeutics Inc's Additional Paid In Capital amounts to 114.7m USD.
What is Qualigen Therapeutics Inc's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 5Y
10%
10%
Over the last year, the Additional Paid In Capital growth was 4%. The average annual Additional Paid In Capital growth rates for Qualigen Therapeutics Inc have been 10% over the past three years , 10% over the past five years .
You don't have any saved screeners yet
